GET DAILY SIGNALSCandel Therapeutics (CADL) Stock Declines -32% Over 30 Days on Delayed FDA Filing
Key Takeaways
- Candel Therapeutics shares have fallen roughly 32% over the last 30 days, from about $9.07 to $6.21, driven primarily by a delayed FDA filing timeline for its lead drug candidate.
- The sharpest decline followed the company's disclosure that it now expects to submit its Biologics License Application (BLA) for aglatimagene in mid-2027, rather than in the fourth quarter of 2026.
- The setback prompted price-target reductions from analysts at Stifel and Canaccord Genuity, even as both firms maintained Buy ratings on the stock.
- Candel's third-quarter 2026 net loss widened to $21.9 million from $11.3 million a year earlier, while cash and equivalents stood at $203.1 million, funding operations into the second quarter of 2028.
- The stock's longer three-month trend is also negative, with shares down roughly 47% from a level near $11.80 in mid-August.
Candel Therapeutics (CADL) Company Background and Pipeline Focus
Candel Therapeutics is a clinical-stage biopharmaceutical company based in Needham, Massachusetts, developing viral and multimodal immunotherapies designed to improve outcomes for patients with cancer. Its lead candidate, aglatimagene besadenovec, is being studied as a treatment for localized prostate cancer in combination with radiation therapy, as well as in non-small cell lung cancer. The pipeline also includes linoserpaturev, an experimental therapy for recurrent high-grade glioma, a form of brain cancer.
Investors follow CADL closely because aglatimagene represents a potential first new therapy in the localized prostate cancer setting in more than two decades. In its pivotal late-stage trial, aglatimagene plus external beam radiation delivered a 41% reduction in the risk of recurrence or prostate cancer-specific death compared with radiation alone, after a median of 58 months of follow-up. A successful regulatory filing and approval would transition Candel from clinical-stage development toward commercialization. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Candel Therapeutics (CADL) Stock Price Moves: Last 30 Days and Quarter
Over the last 30 days, CADL shares have declined roughly 32%, moving from a closing price of about $9.07 to approximately $6.21. The move was heavily concentrated in the final sessions of the period, when the company announced a delay to its planned FDA application.
The longer three-month trend has been weaker still. From a level near $11.80 in mid-August, the stock has fallen roughly 47%, giving back most of the gains built up earlier in the year. The decline reflects both a broader pullback from summer highs and the recent regulatory-timeline setback, which reset investor expectations for when Candel might reach commercialization.
Factors Behind the Recent 30-Day Decline in CADL
The dominant catalyst over the last 30 days was Candel's announcement that it now plans to submit its BLA for aglatimagene in localized prostate cancer in the middle of 2027, rather than in the fourth quarter of 2026. The company attributed the shift to timelines associated with certain assay refinements and noted the final submission date remains subject to ongoing discussions with the U.S. Food and Drug Administration.
Because the BLA is central to Candel's transition toward commercialization, the delay pushed the potential launch window further out and elevated investor concerns about regulatory risk. In response, Stifel lowered its price target to $19 from $22 while maintaining a Buy rating, and Canaccord Genuity reduced its target to $13 from $25 while also keeping a Buy rating. From what I see, this kind of timeline adjustment often triggers quick repricing in clinical-stage names.
The selloff was compounded by third-quarter results reported alongside the update. Candel's net loss widened to $21.9 million from $11.3 million in the prior-year period, as research and development spending nearly doubled to $15.6 million and general and administrative expenses rose to $7.4 million. The company ended the quarter with $203.1 million in cash, which management expects to fund operations into the second quarter of 2028.
Broader Three-Month Trend and Market Context for CADL
Over the past three months, Candel's stock has trended lower after reaching elevated levels during the summer. Earlier in 2026, the shares benefited from strong clinical data readouts for aglatimagene in localized prostate cancer, which lifted sentiment and analyst price targets. As the stock pulled back from those highs, investor focus shifted to execution and regulatory milestones.
The recent BLA delay reinforced a broader theme for the quarter: that a clinical-stage oncology developer's valuation can remain highly sensitive to timeline shifts even when trial data are positive. While Candel continued to present supporting biomarker and survival data at the SITC 2026 annual meeting, the rescheduled filing has reset near-term expectations and left the stock trading well below its earlier quarterly levels. I’m watching this closely as the data support remains intact but the path to approval has lengthened.
Key Drivers to Monitor for Candel Therapeutics (CADL) Going Forward
The most important factor for Candel going forward is the timing and outcome of its ongoing dialogue with the FDA regarding the aglatimagene BLA submission, now expected in mid-2027. Any further clarification on assay requirements or a change in the anticipated filing date is likely to move the stock.
Investors should also monitor Candel's cash position and burn rate. With $203.1 million on hand funding operations into the second quarter of 2028, the runway relative to a potentially later commercial launch remains a key consideration. Additional clinical data readouts across the prostate cancer, non-small cell lung cancer, and glioblastoma programs, along with any analyst rating or price-target revisions, are likely to influence sentiment. As with all clinical-stage biopharmaceutical companies, regulatory, execution, and financing risks remain central to the investment case.
Using AI Tools in My Research Process
In my analysis of names like CADL, I occasionally turn to Tickeron’s AI tools to cross-check patterns and peer comparisons. One platform I find particularly helpful is the AI Screener, which lets me quickly filter for similar clinical-stage biotechs and review historical performance around regulatory events. This helps add context without replacing fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CADL saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for CADL moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 49 similar instances where the indicator exited the overbought zone. In 44 of the 49 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CADL as a result. In 86 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for CADL turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CADL entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CADL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +18.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CADL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.308) is normal, around the industry mean (3.498). P/E Ratio (-5.952) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology